CTRI/2022/10/046392已完成1 期
A Single Arm, Open Label, Single Dose and Multiple Dose Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy Adult Human Subjects.
AXAI LIFE SCIENCES PVT. LTD.,0 个研究点目标入组 6 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •A subject will fulfill all the following criteria to be included in the present study:
- •Willing to provide audio-visual & written informed consent for participation in the study, and an ability to comprehend the nature and purpose of the study.
- •Willing to be available for the entire study period and to comply with protocol requirements.
- •Should have reliable access to the clinical trial center and available in the area for at least one
- •Normal, healthy, adult, human subject of 18-45 years (both inclusive) of age.
- •Body mass index in the range of 18 –30 kg/m2
- •(both inclusive).
- •Healthy volunteers who are clinically non anemic will be included as per the discretion of
- •PI/CI/Physician.
- •Non-diabetic healthy adult with HbA1c < 5.5 at the time of study entry
- •Normal health status as determined by baseline medical and medication history, at the time of
- •screening and vital signs (blood pressure, pulse rate, respiratory rate, and axillary temperature)
- •measurements and physical examination at the time screening as well as check-in during each
- •study period.
- •With normal or clinically non-significant laboratory values as determined by hematological,
- •biochemistry tests and urine analysis.
- •With a normal or clinically non-significant 12-lead ECG.
- •With a negative test for Human Immunodeficiency Virus (HIV) type I/II antibodies or Hepatitis
- •B surface antigen (HBsAg) or Hepatitis C virus antibodies.
- •Non-smokers and should not have been consuming any kind of tobacco products including
- •chewing or inhaling tobacco in the form of jarda, pan, gutkha etc,
- •In case of smokers, they should be willing to abstain from smoking or chewing any tobacco
- •containing product for at least 72.00 hours prior to check-in and throughout the duration of the
- •study till safety samples are collected at the end of the study.
- •In case of female subjects:
- •Negative urine pregnancy test during screening and negative serum ß-hCG test at check-in.
- •Female subjects with childbearing potential must either abstain from sexual intercourse or use acceptable methods of birth control for at least 15 days before 1st dose till 15 days post last-dose/ entire study period [Acceptable birth control methods include barrier methods such as diaphragm/condom with or without spermicide or who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed)].
- •They should not be on their menstruation (bleeding per vaginum) on the day of the withdrawal of blood, when blood is collected for the purpose of study. Ability to communicate effectively. With normal or clinically non-significant laboratory values as determined by hematological, biochemistry tests and urine analysis
排除标准
- •A subject fulfilling any one of the following criteria will be excluded from the study:
- •History of allergy or hypersensitivity intolerance to Dexamethasone or its formulation excipients
- •which, in the opinion of the clinical investigator, would compromise the safety of the subject or the study.
- •Has consumed dexamethasone or any other corticosteroid oral or intravenous for any reasons in past 4 weeks before study entry.
- •Haemoglobin level less than 12.5 grams per deciliter for men and 12 grams per deciliter for
- •Any medical or surgical conditions, which might significantly interfere with the normal functioning of the body or blood forming organs.
- •History of severe infection or major surgery in the past 6 months.
- •History of Minor surgery or fracture within the past 3 months.
- •Significant history or current evidence of malignancy or chronic - infectious, cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic (endocrine), hematological, gastrointestinal, immunological or psychiatric diseases, or organ dysfunction.
- •Any major illness or hospitalized within 90 days prior to check-in.
- •Any other clinical condition like diarrhea or vomiting within three days prior to dosing.
- •Subjects who have been on an unusual or abnormal diet, for whatever reason e.g. because of fasting due to religious reasons during the four weeks before screening.
- •Use of any depot injection or an implant of any drug within three months prior to dosing and throughout the study periods.
- •Use of any prescribed medication (including herbal medicines and vitamin supplements) within 14 days or within five half-lives of the drug, whichever is longer prior to dosing and throughout the duration of the study until the post study safety sample is collected.
- •Use of any OTC products within 7 days or within five half-lives of the drug, whichever is longer
- •prior to first check-in and throughout the duration of the study until the post study safety sample is collected.
- •History or presence of gastric or duodenal ulcer or GI bleeding or blood in stools anytime in the
- •Use of any recreational drug or history of drug addiction.
- •Participated in any clinical investigation requiring repeated blood sampling, blood donation, or have blood loss of >300 mL in past 90 days prior to dosing.
- •Participated in any clinical study within the past 90 days prior to check-in.
- •Use of any Investigational vaccine within the last three years except for Covid-19 vaccines.
- •History of Chronic systemic immunosuppressive medications usage for any reasons.
- •Consumption of alcohol or alcoholic products within 72.00 hrs prior to dosing in each study
- •period and throughout sampling time points.
- •Positive alcohol breath or urine screen for drug of abuse tests during check-in study period.
- •Positive test for alcohol in breath, or drugs of abuse (including benzodiazepines, amphetamines, barbiturates, cocaine, methadone, phencyclidine, 3,4-methylenedioxymethamphetamine [MDMA/ecstasy], tetrahydrocannabinol, and opiates) in urine.
- •Consumption of xanthine or its derivative containing food or beverages (e.g. chocolates, tea,
研究者
相似试验
已完成
1 期
Study to evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human subjectsCTRI/2022/09/045647AXAI LIFE SCIENCES PVT LTD6
尚未招募
1 期
To assess safety and efficacy of PNB028 in colon or pancreatic cancer patients.CTRI/2024/01/062125PNB Vesper Life Science Private Limited
进行中（未招募）
1 期
Study to evaluate QR-110 in subjects with Leber’s Congenital Amaurosis (LCA) due to the p.Cys998X mutation in the CEP290 Geneeber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 GeneMedDRA version: 19.1Level: PTClassification code 10070667Term: Leber's congenital amaurosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-000813-22-BEProQR Therapeutics12
招募中
不适用
Phase I clinical trial to investigate the safety, tolerability and pharmacokinetics of NewGenNafamostat in healthy male subjectsCertain infectious and parasitic diseasesKCT0005647ewGen Therapeutics32
已完成
不适用
An Open Label, Multicentre, Multi-Dose, Single Arm Treatment Clinical Trial in Human Adult, Patients With Mild COVID-19.CTRI/2021/05/033846Martin Sinclair BB Corp15